Clinical TrialApr 22, 2026, 04:07 PM
LB Pharma Publishes Positive Phase 2 Schizophrenia Data for LB-102
AI Summary
LB Pharmaceuticals announced the publication of positive Phase 2 NOVA-1 trial results for LB-102 in acute schizophrenia in JAMA Psychiatry. The trial demonstrated statistically significant benefits, rapid onset, sustained effect, and a favorable safety profile. LB-102 is currently in a pivotal Phase 3 NOVA-2 trial for schizophrenia, with topline data expected in 2H 2027, and is also being evaluated for bipolar depression and adjunctive major depressive disorder.
Key Highlights
- Positive Phase 2 NOVA-1 trial results for LB-102 in schizophrenia published in JAMA Psychiatry.
- LB-102 showed statistically significant benefit and a favorable safety profile.
- Pivotal Phase 3 NOVA-2 trial for schizophrenia is ongoing, enrolling approximately 460 patients.
- Topline data from Phase 3 NOVA-2 trial anticipated in the second half of 2027.
- LB-102 is also in Phase 2 for bipolar depression, with an MDD trial planned for early 2027.